SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets
SSY Group Limited (HKG: 2005) announced it has signed a letter of intent with fellow...
Deals
Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies
Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple...
Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases
Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of...
Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design
Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company...
Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD
Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks...
Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery
H. Lundbeck A/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle,...
Medtronic Makes Strategic ICE Catheter Investments to Strengthen Cardiac Ablation Leadership and Affera Ecosystem Integration
Medtronic plc (NYSE: MDT) announced on June 3, 2026, strategic investments in two privately held...
Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has significantly expanded its collaboration with fellow US biotechnology company...
Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases
Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research...
Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical...
Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China
Wuhan Kadwise Biotechnology Co., Ltd., a China-based gynecologic oncology specialist with extensive expertise in genetic...
Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market
Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX),...
Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets
Rallybio Corporation (NASDAQ: RLYB) announced a definitive agreement to acquire Avenzo Therapeutics, Inc. through a...
Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China
Simcere Pharmaceutical Group Limited (HKG: 2096) announced a strategic commercial partnership with PrimeGenX Therapeutics Co.,...
Servier Group Acquires Edgewise Therapeutics’ Muscular Dystrophy Business for Up to $2.65 Billion
Servier Group, the French pharmaceutical company, announced a definitive agreement to acquire the muscular dystrophy...
HemaCell Therapeutics Secures $44 Million Series B to Advance World’s First Megakaryocyte Injection for Platelet Regeneration
Suzhou HemaCell Therapeutics (HemaCell), a pioneering cell therapy developer focused on platelet regeneration, announced the...
Haisco Pharmaceutical and Eli Lilly Forge $3 Billion Drug Discovery Alliance Spanning Multiple Therapeutic Areas
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) and Eli Lilly and Company (NYSE: LLY) announced...
Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon
Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG...
Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement
Hanmi Pharm. Co., Ltd. (“Hanmi”) announced a strategic global licensing agreement with Eli Lilly (NYSE:...
True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations
Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture...